SCHEMBL26328176

SCHEMBL26328176

CCc1cc(Nc2ccc3c(c2)CN(c2cccc(Oc4ccncc4)c2)C3=O)ccn1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 4/20 0.37
CYP11B1 P15538 2/20 0.37
PIK3CG P48736 2/20 0.34
EGFR P00533 1/20 0.33
MAPK13 O15264 1/20 0.33
SCN9A Q15858 1/20 0.33
NR1H4 Q96RI1 1/20 0.33
GRM2 Q14416 1/20 0.33
RAF1 P04049 1/20 0.32
NPC1 O15118 1/20 0.32
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
SLC6A2 P23975 4/20 0.32
CACNA2D1 P54289 4/20 0.32
PPARG P37231 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24003929 0.88 CYP11B2 (0.39) CYP11B2CYP11B1PIK3CGEGFRMAPK13
SCHEMBL25820876 0.82 NPC1 (0.38) CYP11B2CYP11B1PIK3CGGRM2NPC1
SCHEMBL26332893 0.82 MAPK1 (0.38) CYP11B2CYP11B1EGFRNPC1RAB9A
SCHEMBL25827086 0.81 CYP11B2 (0.39) CYP11B2CYP11B1EGFRMAPK13SCN9A
SCHEMBL24010356 0.81 MAPK13 (0.38) CYP11B2MAPK13GRM2RAF1NPC1
SCHEMBL25820871 0.81 MEN1 (0.39) CYP11B2CYP11B1PIK3CGSCN9AGRM2
SCHEMBL26322994 0.80 CYP11B2 (0.37) CYP11B2CYP11B1PIK3CGNR1H4
SCHEMBL24003953 0.79 MET (0.38) CYP11B2CYP11B1PIK3CGSCN9AGRM2
SCHEMBL30232527 0.79 MET (0.38) CYP11B2CYP11B1PIK3CGSCN9AGRM2
SCHEMBL24003910 0.78 CYP11B2 (0.48) CYP11B2CYP11B1PIK3CGEGFRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295114-A1 AKT3 MODULATORS AKT3, AKT2, MTOR CYP11B2 860/4885CYP11B1 751/4885PIK3CG 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.